Important Notice for Intellia Therapeutics, Inc. (NTLA) Shareholders: Potential Securities Class Action Lawsuit
New York, NY, March 20, 2025 – The Gross Law Firm, a leading national securities fraud class action law firm, notifies investors of a potential securities class action lawsuit against Intellia Therapeutics, Inc. (NASDAQ: NTLA).
The potential class action concerns allegations of securities fraud against Intellia Therapeutics and certain of its top executives. The complaint, filed in the United States District Court for the District of Massachusetts, alleges that the defendants made materially false and misleading statements regarding the company’s gene-editing therapy, known as CRISPR, and its potential for treating various diseases.
Class Period and Eligibility
The class period for this potential lawsuit is from May 13, 2021, to December 15, 2022. Shareholders who purchased or acquired Intellia Therapeutics securities during this timeframe are encouraged to contact The Gross Law Firm to discuss their legal rights and potential eligibility to serve as a lead plaintiff.
Background
Intellia Therapeutics is a biotechnology company that focuses on the development of CRISPR/Cas9 gene-editing technology for therapeutic applications. The company’s lead program, known as INT-200, is designed to treat transthyretin amyloid cardiomyopathy (ATTR cm).
In May 2021, Intellia Therapeutics announced positive results from a Phase 1 study of its INT-200 therapy. The company reported that the therapy met its primary and secondary endpoints, demonstrating a significant reduction in serum transthyretin (TTR) levels and a favorable safety profile. These results were hailed as a major breakthrough in the field of gene-editing therapies.
Allegations of Securities Fraud
However, in December 2022, a series of reports emerged questioning the validity of the INT-200 study results. Several independent researchers raised concerns about the accuracy of the data presented by Intellia Therapeutics, leading to a significant decline in the company’s stock price.
The Gross Law Firm’s complaint alleges that Intellia Therapeutics and its executives made materially false and misleading statements regarding the INT-200 program, including its safety and efficacy, and failed to disclose material information about the potential issues with the study data.
Possible Impact on Shareholders
Shareholders who purchased Intellia Therapeutics securities during the class period may have suffered significant losses due to the alleged securities fraud. If the case proceeds as a class action, these shareholders could be eligible to recover their damages.
Impact on the Biotechnology Industry and Gene-Editing Therapies
The potential Intellia Therapeutics lawsuit raises important questions about the regulatory oversight and data integrity in the biotechnology industry, particularly in the field of gene-editing therapies. If the allegations are proven true, it could lead to increased scrutiny and potential regulatory action against other companies in the space.
Contact The Gross Law Firm
If you purchased or acquired Intellia Therapeutics securities during the class period, you may be entitled to join this potential securities class action lawsuit. To learn more about your legal rights and potential eligibility to serve as a lead plaintiff, please contact The Gross Law Firm at (212) 509-1441 or fill out the form on our website, [email protected], or visit our website at www.grosslawfirm.com/intellia-therapeutics-ntla.
The Gross Law Firm represents investors worldwide, and the firm’s securities fraud litigation spans over four decades. The firm’s attorneys have recovered billions of dollars for victims of securities fraud, and they are committed to fighting for justice on behalf of their clients.
Conclusion
The potential Intellia Therapeutics securities class action lawsuit highlights the importance of transparency and data integrity in the biotechnology industry, particularly in the rapidly evolving field of gene-editing therapies. Shareholders who purchased Intellia Therapeutics securities during the class period are encouraged to contact The Gross Law Firm to discuss their possible legal rights and potential eligibility to serve as a lead plaintiff.
If you have any questions or concerns, please don’t hesitate to contact The Gross Law Firm at (212) 509-1441 or visit our website at www.grosslawfirm.com.
- Intellia Therapeutics, Inc. (NASDAQ: NTLA)
- Potential securities class action lawsuit
- Allegations of securities fraud
- Class period: May 13, 2021, to December 15, 2022
- Shareholders encouraged to contact The Gross Law Firm
- Impact on shareholders and the biotechnology industry
